Currently, the current strategies for preventing relapse in ALL include immunotherapies, such as blinatumomab, a bispecific T-cell engager (BiTE), with one arm targeting CD19 on B-ALL blasts and the other arm binding to CD3ζ on T cells. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.